Literature DB >> 9653106

An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene.

M A Morsy1, M Gu, S Motzel, J Zhao, J Lin, Q Su, H Allen, L Franlin, R J Parks, F L Graham, S Kochanek, A J Bett, C T Caskey.   

Abstract

Adenoviral (Ad)-mediated in vivo gene transfer and expression are limited in part by cellular immune responses to viral-encoded proteins and/or transgene immunogenicity. In an attempt to diminish the former responses, we have previously developed and described helper-dependent (HD) Ad vectors in which the viral protein coding sequences are completely eliminated. These HD vectors have up to 37 kb insert capacity, are easily propagated in a Cre recombinase-based system, and can be produced to high concentration and purity (>99.9% helper-free vector). In this study, we compared safety and efficacy of leptin gene delivery mediated by an HD vector (HD-leptin) and a first-generation E1-deleted Ad vector (Ad-leptin) in normal lean and ob/ob (leptin-deficient) mice. In contrast to evidence of liver toxicity, inflammation, and cellular infiltration observed with Ad-leptin delivery in mice, HD-leptin delivery was associated with a significant improvement in associated safety/toxicity and resulted in efficient gene delivery, prolonged elevation of serum leptin levels, and associated weight loss. The greater safety, efficient gene delivery, and increased insert capacity of HD vectors are significant improvements over current Ad vectors and represent favorable features especially for clinical gene therapy applications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653106      PMCID: PMC20895          DOI: 10.1073/pnas.95.14.7866

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Immune responses to adenoviral vectors during gene transfer in the brain.

Authors:  K Kajiwara; A P Byrnes; H M Charlton; M J Wood; K J Wood
Journal:  Hum Gene Ther       Date:  1997-02-10       Impact factor: 5.695

2.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.

Authors:  S Worgall; G Wolff; E Falck-Pedersen; R G Crystal
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

3.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.

Authors:  R J Parks; L Chen; M Anton; U Sankar; M A Rudnicki; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

4.  Construction of adenovirus vectors through Cre-lox recombination.

Authors:  S Hardy; M Kitamura; T Harris-Stansil; Y Dai; M L Phipps
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes.

Authors:  S E Haecker; H H Stedman; R J Balice-Gordon; D B Smith; J P Greelish; M A Mitchell; A Wells; H L Sweeney; J M Wilson
Journal:  Hum Gene Ther       Date:  1996-10-01       Impact factor: 5.695

6.  Yeast ARS function and nuclear matrix association coincide in a short sequence from the human HPRT locus.

Authors:  R C Sykes; D Lin; S J Hwang; P E Framson; A C Chinault
Journal:  Mol Gen Genet       Date:  1988-05

7.  Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts.

Authors:  H Gahéry-Ségard; V Juillard; J Gaston; R Lengagne; A Pavirani; P Boulanger; J G Guillet
Journal:  Eur J Immunol       Date:  1997-03       Impact factor: 5.532

8.  Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice.

Authors:  H Lochmüller; B J Petrof; G Pari; N Larochelle; V Dodelet; Q Wang; C Allen; S Prescott; B Massie; J Nalbantoglu; G Karpati
Journal:  Gene Ther       Date:  1996-08       Impact factor: 5.250

9.  Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis.

Authors:  K J Fisher; H Choi; J Burda; S J Chen; J M Wilson
Journal:  Virology       Date:  1996-03-01       Impact factor: 3.616

10.  Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes.

Authors:  M A Morsy; J Z Zhao; T T Ngo; A W Warman; W E O'Brien; F L Graham; C T Caskey
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

View more
  71 in total

1.  Frequency and stability of chromosomal integration of adenovirus vectors.

Authors:  A Harui; S Suzuki; S Kochanek; K Mitani
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 2.  The promise and potential hazards of adenovirus gene therapy.

Authors:  L S Young; V Mautner
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

3.  Optimization of the helper-dependent adenovirus system for production and potency in vivo.

Authors:  V Sandig; R Youil; A J Bett; L L Franlin; M Oshima; D Maione; F Wang; M L Metzker; R Savino; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

4.  Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector.

Authors:  A Recchia; R J Parks; S Lamartina; C Toniatti; L Pieroni; F Palombo; G Ciliberto; F L Graham; R Cortese; N La Monica; S Colloca
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

5.  Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression.

Authors:  X Wang; W Zeng; M Murakawa; M W Freeman; B Seed
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer.

Authors:  M Hillgenberg; H Tönnies; M Strauss
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system.

Authors:  Philip Ng; Carole Evelegh; Derek Cummings; Frank L Graham
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 8.  Vectors for gene therapy of cardiovascular disease.

Authors:  J F Dedieu; A Mahfoudi; A Le Roux; D Branellec
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

9.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.

Authors:  D Maione; C Della Rocca; P Giannetti; R D'Arrigo; L Liberatoscioli; L L Franlin; V Sandig; G Ciliberto; N La Monica; R Savino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 10.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.